Yang Lin

Dr. Yang Lin

Weill Cornell Medicine, 505 East 70th Street, 1320 York Avenue, New York, NY 10021, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
BPBrisa Palikuqi
Brisa Palikuqi
DNDuc-Huy T. Nguyen
Duc-Huy T. Nguyen
GLGe Li
Ge Li
RSRyan Schreiner
Ryan Schreiner
APAlessandro F. Pellegata
Alessandro F. Pellegata
SRShahin Rafii
Shahin Rafii

1 March 2018 in Cell Stem Cell
Verified
Journal Article
Closed access
TWTaku Wakabayashi
Taku Wakabayashi
HNHisamichi Naito
Hisamichi Naito
JSJun-Ichi Suehiro
Jun-Ichi Suehiro
YLYang Lin
Yang Lin
HKHideya Kawaji
Hideya Kawaji
NTNobuyuki Takakura
Nobuyuki Takakura

1 May 2013 in Development
Verified
Journal Article
Closed access
PDF file
HCHanying Chen
Hanying Chen
WZWenjun Zhang
Wenjun Zhang
XSXiaoxin Sun
Xiaoxin Sun
MYMomoko Yoshimoto
Momoko Yoshimoto
ZCZhuang Chen
Zhuang Chen
Weinian ShouWeinian Shou
Weinian Shou
Trabeculation and compaction of the embryonic myocardium are morphogenetic events crucial for the formation and function of the ventricular walls. Fkbp1a (FKBP12) is a ubiquitously expressed cis-trans peptidyl-prolyl isomerase. Fkbp1a-deficient mice develop ventricular hypertrabeculation and noncompaction. To determine the physiological function of Fkbp1a in regulating the intercellular and intracellular signaling pathways involved in ventricular trabeculation and compaction, we generated a series of Fkbp1a conditional knockouts. Surprisingly, cardiomyocyte-restricted ablation of Fkbp1a did not give rise to the ventricular developmental defect, whereas endothelial cell-restricted ablation of Fkbp1a recapitulated the ventricular hypertrabeculation and noncompaction observed in Fkbp1a systemically deficient mice, suggesting an important contribution of Fkbp1a within the developing endocardia in regulating the morphogenesis of ventricular trabeculation and compaction. Further analysis demonstrated that Fkbp1a is a novel negative modulator of activated Notch1. Activated Notch1 (N1ICD) was significantly upregulated in Fkbp1a-ablated endothelial cells in vivo and in vitro. Overexpression of Fkbp1a significantly reduced the stability of N1ICD and direct inhibition of Notch signaling significantly reduced hypertrabeculation in Fkbp1a-deficient mice. Our findings suggest that Fkbp1a-mediated regulation of Notch1 plays an important role in intercellular communication between endocardium and myocardium, which is crucial in controlling the formation of the ventricular walls.

1 November 2017 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
YLYang Lin
Yang Lin
CGChang-Hyun Gil
Chang-Hyun Gil
MYMervin C. Yoder
Mervin C. Yoder
The emergence of induced pluripotent stem cell (iPSC) technology paves the way to generate large numbers of patient-specific endothelial cells (ECs) that can be potentially delivered for regenerative medicine in patients with cardiovascular disease. In the last decade, numerous protocols that differentiate EC from iPSC have been developed by many groups. In this review, we will discuss several common strategies that have been optimized for human iPSC-EC differentiation and subsequent studies that have evaluated the potential of human iPSC-EC as a cell therapy or as a tool in disease modeling. In addition, we will emphasize the importance of using in vivo vessel-forming ability and in vitro clonogenic colony–forming potential as a gold standard with which to evaluate the quality of human iPSC-EC derived from various protocols.

4 August 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MKMichihiro Kobayashi
Michihiro Kobayashi
WSW. Christopher Shelley
W. Christopher Shelley
WSWooseok Seo
Wooseok Seo
SVSasidhar Vemula
Sasidhar Vemula
YLYang Lin
Yang Lin
MYMomoko Yoshimoto
Momoko Yoshimoto
The fetal liver is a major hematopoietic site containing progenitor cells that give rise to nearly all blood cells, including B-1 cells. Because the fetal liver is not a de novo site of hematopoietic stem cell (HSC) or progenitor-cell emergence, it must be seeded by yolk sac (YS)-derived erythromyeloid progenitors at embryonic day (E) 8.5–E10 and aorta-gonado-mesonephros (AGM)-derived HSCs at E10.5–E11.5. Although the B-1 progenitor cell pool in the fetal liver is considered to be of HSC origin, we have previously proposed that YS-derived B-1 progenitors may also contribute to this pool. Until now, it has been impossible to determine whether HSC-independent B-1 progenitor cells exist in the fetal liver. Here, we demonstrate the presence of transplantable fetal-liver B-1 and marginal zone B progenitor cells in genetically engineered HSC-deficient embryos. HSC-deficient YS and AGM tissues produce B-1 progenitors in vitro and thus may serve as sites of origin for the B-1 progenitors that seed the fetal liver. Furthermore, we have found that core-binding factor beta (Cbfβ) expression is required for fetal-liver B-1 progenitor cell maturation and expansion. Our data provide, to our knowledge, the first evidence for the presence of B-1 progenitor cells in the fetal liver that arise independently of HSCs and implicate Cbfβ as a critical molecule in the development of this lineage. Significance All lymphoid cells are considered to be products of hematopoietic stem cells (HSCs); however, it has been suggested, but not proven, that innate immune B-1 progenitor cells develop independently of HSCs in the fetal liver. B-1 cells, especially B-1a cells, are not replaced by adult bone marrow transplantation. Thus, it is critical to understand the origin and mechanisms required to sustain these cells in vivo because B-1 cells play important roles in the first line of defense against microbial infection and in preventing organ damage in autoimmune patients and infections in some patients after bone-marrow transplantation. We demonstrate that B-1 progenitor cells can develop independently of HSCs in the fetal liver and that their development relies critically on the expression of core-binding factor beta.

13 January 2014 in Stem Cells and Development
Verified
Journal Article
Closed access
YLYang Lin
Yang Lin
MYMervin C. Yoder
Mervin C. Yoder
MYMomoko Yoshimoto
Momoko Yoshimoto
Mammalian embryos produce several waves of hematopoietic cells before the establishment of the hematopoietic stem cell (HSC) hierarchy. These early waves of embryonic hematopoiesis present a reversed hierarchy in which hematopoietic potential is first displayed by highly specialized cells that are derived from transient uni- and bipotent progenitor cells. Hematopoiesis progresses through multilineage erythro-myeloid progenitor cells that lack self-renewal potential and, subsequently, to make distinct lymphoid progenitor cells before culminating in detectable definitive HSC. This review provides an overview of the stepwise development of embryonic hematopoiesis. We focus on recent progress in demonstrating that lymphoid lineages emerge from hemogenic endothelial cells before the presence of definitive HSC activity and discuss the implications of these findings.